The clinical trial, involving 98 patients, highlighted the efficacy of a 450 mg dosage administered every four weeks. In active thyroid eye disease (TED) patients, the treatment achieved an 81% proptosis response by week 12, while chronic TED patients saw a 76% response rate at week 24. Beyond physical improvements, 84% of active TED participants reached a Clinical Activity Score of 0 or 1, indicating a successful suppression of inflammatory symptoms.

Safety data offered a critical advantage for the drug, particularly regarding concerns over hearing side effects often associated with IGF-1R inhibitors. Minghui reported that all documented hearing-related adverse events were limited to Grade 1 severity, with no instances of severe or permanent damage. CEO Guoqing Cao noted that the antibody is designed to block both IGF-1 and IGF-2 signaling, which likely contributes to the observed clinical outcomes.

With these results, Minghui is accelerating its development timeline. Phase III trials are currently underway in China, with results expected in the third quarter of 2026. Simultaneously, the company is preparing for global Phase III enrollment, slated to begin in the final quarter of 2026.